These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 17260953)

  • 61. The intact human acetylcholinesterase C-terminal oligomerization domain is alpha-helical in situ and in isolation, but a shorter fragment forms beta-sheet-rich amyloid fibrils and protofibrillar oligomers.
    Cottingham MG; Voskuil JL; Vaux DJ
    Biochemistry; 2003 Sep; 42(36):10863-73. PubMed ID: 12962511
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Inherent Biophysical Properties Modulate the Toxicity of Soluble Amyloidogenic Light Chains.
    Maritan M; Romeo M; Oberti L; Sormanni P; Tasaki M; Russo R; Ambrosetti A; Motta P; Rognoni P; Mazzini G; Barbiroli A; Palladini G; Vendruscolo M; Diomede L; Bolognesi M; Merlini G; Lavatelli F; Ricagno S
    J Mol Biol; 2020 Feb; 432(4):845-860. PubMed ID: 31874151
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Counteracting effects of renal solutes on amyloid fibril formation by immunoglobulin light chains.
    Kim YS; Cape SP; Chi E; Raffen R; Wilkins-Stevens P; Stevens FJ; Manning MC; Randolph TW; Solomon A; Carpenter JF
    J Biol Chem; 2001 Jan; 276(2):1626-33. PubMed ID: 11050093
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Structure and antigenic behaviour of kappa I-immunoglobulin light-chain amyloid proteins.
    Westermark P; Sletten K; Natvig JB
    Acta Pathol Microbiol Scand C; 1981 Jun; 89(3):199-203. PubMed ID: 6171994
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Towards understanding the structure-function relationship of human amyloid disease.
    Dealwis C; Wall J
    Curr Drug Targets; 2004 Feb; 5(2):159-71. PubMed ID: 15011949
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A single mutation at the sheet switch region results in conformational changes favoring lambda6 light-chain fibrillogenesis.
    Hernández-Santoyo A; del Pozo Yauner L; Fuentes-Silva D; Ortiz E; Rudiño-Piñera E; Sánchez-López R; Horjales E; Becerril B; Rodríguez-Romero A
    J Mol Biol; 2010 Feb; 396(2):280-92. PubMed ID: 19941869
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient.
    Swuec P; Lavatelli F; Tasaki M; Paissoni C; Rognoni P; Maritan M; Brambilla F; Milani P; Mauri P; Camilloni C; Palladini G; Merlini G; Ricagno S; Bolognesi M
    Nat Commun; 2019 Mar; 10(1):1269. PubMed ID: 30894521
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effects of oxidative post-translational modifications on structural stability and self-assembly of λ6 immunoglobulin light chain.
    Zottig X; Laporte Wolwertz M; Golizeh M; Ohlund L; Sleno L; Bourgault S
    Biophys Chem; 2016 Dec; 219():59-68. PubMed ID: 27744229
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Primary amyloidosis associated with a novel heavy-chain fragment (AH amyloidosis).
    Solomon A; Weiss DT; Murphy C
    Am J Hematol; 1994 Feb; 45(2):171-6. PubMed ID: 8141123
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Diagnostic and therapeutic potential of amyloid-reactive IgG antibodies contained in human sera.
    O'Nuallain B; Hrncic R; Wall JS; Weiss DT; Solomon A
    J Immunol; 2006 Jun; 176(11):7071-8. PubMed ID: 16709869
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Application of monoclonal anti-idiotypes in the study of AL amyloidosis: therapeutic implications.
    Bellotti V; Stoppini M; Perfetti V; Zorzoli I; Marinone G; Maggi A; Invernizzi R; Arbustini E; Merlini G
    Ren Fail; 1993; 15(3):365-71. PubMed ID: 8516492
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Use of an anti-idiotypic monoclonal antibody in studying amyloidogenic light chains in cells, urine and fibrils: pathophysiology and clinical implications.
    Bellotti V; Stoppini M; Perfetti V; Zorzoli I; Marinone G; Invernizzi R; Zambelli LM; Arbustini E; Grasso M; Ferri G
    Scand J Immunol; 1992 Oct; 36(4):607-15. PubMed ID: 1411304
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effect of association state and conformational stability on the kinetics of immunoglobulin light chain amyloid fibril formation at physiological pH.
    Souillac PO; Uversky VN; Millett IS; Khurana R; Doniach S; Fink AL
    J Biol Chem; 2002 Apr; 277(15):12657-65. PubMed ID: 11815605
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The critical role of the constant region in thermal stability and aggregation of amyloidogenic immunoglobulin light chain.
    Klimtchuk ES; Gursky O; Patel RS; Laporte KL; Connors LH; Skinner M; Seldin DC
    Biochemistry; 2010 Nov; 49(45):9848-57. PubMed ID: 20936823
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A Conservative Point Mutation in a Dynamic Antigen-binding Loop of Human Immunoglobulin λ6 Light Chain Promotes Pathologic Amyloid Formation.
    Peterle D; Klimtchuk ES; Wales TE; Georgescauld F; Connors LH; Engen JR; Gursky O
    J Mol Biol; 2021 Dec; 433(24):167310. PubMed ID: 34678302
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Optimization of the immunohistochemical diagnosis of AL amyloidosis using novel antibodies].
    Mikhaleva LM; Gioeva ZV; Rëken K
    Arkh Patol; 2015; 77(5):58-63. PubMed ID: 26978022
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Immunohistochemical examination of Aκ amyloidosis with antibody against adjacent portion of the carboxy terminus of immunoglobulin kappa light chain.
    Hoshii Y; Nanbara H; Cui D; Takahashi M; Ikeda E
    Med Mol Morphol; 2012 Jun; 45(3):124-8. PubMed ID: 23001294
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effect of lysine modification on the stability and cellular binding of human amyloidogenic light chains.
    Davern S; Murphy CL; O'Neill H; Wall JS; Weiss DT; Solomon A
    Biochim Biophys Acta; 2011 Jan; 1812(1):32-40. PubMed ID: 20692337
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Solid state NMR assignments of a human λ-III immunoglobulin light chain amyloid fibril.
    Pradhan T; Annamalai K; Sarkar R; Hegenbart U; Schönland S; Fändrich M; Reif B
    Biomol NMR Assign; 2021 Apr; 15(1):9-16. PubMed ID: 32946005
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Epitope-specific antibody fragments block aggregation of AGelD187N, an aberrant peptide in gelsolin amyloidosis.
    Leimu L; Holm P; Gąciarz A; Haavisto O; Prince S; Pesonen U; Huovinen T; Lamminmäki U
    J Biol Chem; 2024 Aug; 300(8):107507. PubMed ID: 38944121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.